CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Nab-paclitaxel +9 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03535727
NCT03535727Phase 2Completed
CompareCT.gov

A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted May 24, 2018·Updated Dec 31, 2024

In Brief

A Phase 2 clinical trial evaluating Nab-paclitaxel, Gemcitabine, and 3 other interventions for Adenocarcinoma and 9 related conditions. Completed, enrolled 48 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular, Neoplasms, Neoplasms Pancreatic, Digestive System Neoplasm, Endocrine Gland Neoplasms, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 24, 2018
Enrollment StartJun 21, 2018
Primary CompletionOct 3, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 8.1 years ago

Interventions

Nab-paclitaxeldrug

IV over 30 minutes; Days 1 and 15

Gemcitabinedrug

IV over 30 minutes; Days 1 and 15

Capecitabinedrug

PO twice daily (BID); Days 1-7, 15-21

Cisplatindrug

IV over 60 minutes; Days 1 and 15

Irinotecandrug

IV over 30 minutes; Days 1 and 15

Nab-paclitaxeldrug

IV over 30 minutes; Days 4 and 11

Gemcitabinedrug

IV over 30 minutes; Days 4 and 11

Capecitabinedrug

PO BID; Days 1- 14

Cisplatindrug

IV over 60 minutes; Days 4 and 11

Irinotecandrug

IV over 30 minutes; Days 4 and 11